Polaryx Therapeutics, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
CEO Alex Yang and CFO G. Michael Landis certified the Q2 2026 10-Q filing (period ended June 30, 2026; filed August 13, 2026) per Sarbanes-Oxley requirements. Both officers attested that financial statements fairly present the company's condition, disclosure controls are effective, and no material weaknesses or fraud involving management were identified. No specific operational, financial, or transactional details are disclosed in these certification exhibits.
Why this rating
Standard required SOX certifications; no business changes, transactions, or financial data disclosed. Purely administrative and routine.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.